Alvogen is an international, privately-owned specialty pharmaceutical company focused on the development, manufacturing and marketing of generic pharmaceuticals, biosimilar products and OTCs (over-the-counter medicines). Alvogen’s lines of business include generic sales and marketing (Gx), product development, contract manufacturing (CMO) and contract research (CRO).
Alvogen in Brief
Alvogen has commercial operations in more than 30 countries and 1,800 employees around the world
We are rethinking generics by creating a radical new business model that enhances quality of life and delivers exceptional value to all our stakeholders.
We are energetic and creative, always seeking to improve. We learn from our successes and failures and we always encourage and support new ideas.
The US market continues to be the most important market for Alvogen. Alvogen business in the US is categorized into two major focus areas; generic pharmaceuticals and sales of third party services, such as contract manufacturing (CMO), pilot plant contract development (CDO) and clinical research (CRO).
Third party contract manufacturing and development services are provided by the Company's manufacturing facility in Norwich located in New York State under the Norwich Pharmaceuticals brand.
Alvogen is an international pharmaceuticals company with offices around the world. With over 200 projects in its product pipeline Alvogen has high ambitions for future growth.